Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China; Tianjin Institute of Digestive Disease, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China.
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China; Tianjin Institute of Digestive Disease, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China.
Biochem Pharmacol. 2023 Jun;212:115546. doi: 10.1016/j.bcp.2023.115546. Epub 2023 Apr 10.
Obesity has become a major public health problem worldwide and its occurrence is increasing globally. Obesity has also been shown to be involved in the occurrence and development of many diseases and pathological conditions, such as nonalcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM), insulin resistance (IR). In recent years, gut microbiota has received extensive attention as an important regulatory part involved in host diseases and health status. A growing body of evidence suggests that gut microbiota dysbiosis has a significant adverse effect on the host. Small intestinal bacterial overgrowth (SIBO), a type of intestinal microbial dysbiosis, has been gradually revealed to be associated with obesity and its related diseases. The presence of SIBO may lead to the destruction of intestinal barrier integrity, increased intestinal permeability, increased endotoxin levels, activation of inflammatory responses, and translocation of bacteria from the colon to the small intestine. However, the causal relationship between SIBO and obesity and the specific mechanisms have not been well elucidated. This review discusses the cross-talk between SIBO and obesity and its related diseases, and expounds its potential mechanisms and interventions, which may help to discover new therapeutic targets for obesity and its related diseases and develop treatment options.
肥胖已成为全球主要的公共卫生问题，其发生率在全球范围内呈上升趋势。肥胖也被证明与许多疾病和病理状况的发生和发展有关，如非酒精性脂肪性肝病（NAFLD）、2 型糖尿病（T2DM）、胰岛素抵抗（IR）。近年来，肠道微生物群作为涉及宿主疾病和健康状况的重要调节部分受到广泛关注。越来越多的证据表明，肠道微生物群失调对宿主有显著的不利影响。小肠细菌过度生长（SIBO）是一种肠道微生物失调，其与肥胖及其相关疾病的关系逐渐被揭示。SIBO 的存在可能导致肠道屏障完整性的破坏、肠道通透性增加、内毒素水平升高、炎症反应的激活以及细菌从结肠向小肠的移位。然而，SIBO 与肥胖及其相关疾病之间的因果关系以及具体机制尚未得到很好的阐明。本综述讨论了 SIBO 与肥胖及其相关疾病之间的相互作用，并阐述了其潜在的机制和干预措施，这可能有助于发现肥胖及其相关疾病的新治疗靶点，并开发治疗方法。
